US FDA Approves Covid-19 Drug of Lilly to be Taken Without Remdesivir

The pharmaceutical company ‘Lilly’ said that, the Food and Drug Administration (FDA) of the United States had widened the emergency use authorization for the baricitinib for the purpose of allowing it for the treatment of the novel corona virus with or without the remdesivir.

The previous emergency use authorization had been restricted for using it only in the combination with the company remdesivir, which is a drug that is produced by the company ‘Gilead Sciences’ based in California.

 The company Lilly said, the emergency use authorization is also provided for the use of baricitinib for the purpose of treatment of the novel corona virus in the adults hospitalized along with the paediatric patients of two years of age or the older people which are requiring the supplemental oxygen, and the company also said that, the revised authorization has been giving the physicians a greater flexibility in how they can be successful in addressing the most urgent medical needs posed by the novel corona virus pandemic.

IIya Yuffa, senior vice president and president of the Lilly Biomedicines said, Baricitinib in the combination with the remdesivir medicine it has already provided many people with an option of the treatment that can possibly help in preventing the progression to the death or ventilation of the patients infected from the novel corona virus pandemic under the current authorized use of the medicine.

IIya Yuffa also said, according to the latest evidence, they are very confident in the potential of the baricitinib as a very important treatment for the hospitalized population of the novel corona virus, which have the need for the supplemental oxygen.